My Favourite 5%+ Yields: GlaxoSmithKline plc, Centrica PLC & Vodafone Group plc

Looking for a great dividend yield? Look no further than GlaxoSmithKline plc (LON:GSK), Centrica PLC (LON:CNA) & Vodafone Group plc (LON:VOD)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Cash

Although there has been a lot of talk recently regarding interest rate rises, it seems clear that rates are unlikely to hit the ‘historic norm’ of 4%-5% for many years to come. Indeed, the Bank of England has even stated that 2%-3% could be the ‘new normal’. With that in mind, high-yielding shares could continue to offer a realistic alternative to savers and income-seeking investors alike. Here are three companies that yield at least 5% and trade at an attractive price.

GlaxoSmithKline

GlaxoSmithKline (LSE: GSK) continues to see its share price underperform due to weak sentiment rather than doubts surrounding its long term potential. The pharmaceutical giant is subject to various bribery allegations that have caused shares in the company to fall by 8% in the last three months alone.

However, with a highly diversified drugs pipeline that has huge potential, GlaxoSmithKline could see its share price rise over the longer term. In the meantime, a dividend yield of 5.5% is highly attractive, while a price to earnings (P/E) ratio of 13.1 highlights that the present time could be an opportunity to buy in at a low price.

Centrica

As with GlaxoSmithKline, Centrica (LSE: CNA) is suffering from weak sentiment. It is set to change its management team in the near future (with BP’s Iain Conn replacing Sam Laidlaw on 1 January 2015) and is subject to continuing uncertainty regarding domestic energy prices post the 2015 general election.

However, the market seems to pricing in these risks, with shares in Centrica currently trading on a P/E ratio of just 12 (versus 13.7 for the FTSE 100). Furthermore, shares in the company currently yield a highly impressive 5.5%, with dividends per share forecast to increase by 3.2% next year. Overall, Centrica seems to offer good value and considerable income potential.

Vodafone

Vodafone’s (LSE: VOD) current yield of 5.5% has come under a degree of scrutiny in recent months. That’s because it currently pays out more money as a dividend than it makes as a profit. As a result, the current level of dividend is unsustainable in the long run.

Despite this, Vodafone could prove to be an attractive income play. That’s because it appears to have a sound long term strategy that could deliver strong growth in profitability moving forward. Indeed, Vodafone’s purchase of high-quality, undervalued assets in Europe may take time to come good, but should ensure that the company is able to sustain an impressive yield in future years. As a result, it remains an attractive income play at current price levels.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Centrica and GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s how I’d aim for a ton of passive income from £20k in an ISA

To get the best passive income from an ISA, I think we need to balance risk with the potential rewards.…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

2 FTSE 100 stocks I’d buy as the blue-chip index hits record highs

This Fool takes a look at a pair of quality FTSE 100 stocks that appear well-positioned for future gains, despite…

Read more »

Satellite on planet background
Small-Cap Shares

Here’s why AIM stock Filtronic is up 44% today

The share price of AIM stock Filtronic has surged on the back of some big news in relation to its…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

At a record high, there can still be bargain FTSE 100 shares to buy!

The FTSE 100 closed at a new all-time high this week. Our writer explains why there might still be bargain…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

After profits plunge 28%, should investors consider buying Lloyds shares?

Lloyds has seen its shares wobble following the release of its latest results. But is this a chance for investors…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

Something’s changed in a good way for Reckitt in Q1, and the share price may be about to take off

With the Reckitt share price near 4,475p, is this a no-brainer stock? This long-time Fool takes a closer look at…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

This new boost in assets might just get the abrdn share price moving again

The abrdn share price has lost half its value in the past five years. But with investor confidence returning, are…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

As revenues rise 8%, is the Croda International share price set to bounce back?

The latest update from Croda International indicates that sales are starting to recover from the end of 2023, so is…

Read more »